Rapid Therapeutic Science Laboratories, Inc. Stock Other OTC
Equities
RTSL
US7534311052
Pharmaceuticals
Sales 2021 | 0 0 | Sales 2022 | - | Capitalization | 5.82M 7.93M |
---|---|---|---|---|---|
Net income 2021 | -2M -2.72M | Net income 2022 | -1M -1.36M | EV / Sales 2021 | 93,978,853,933 x |
Net Debt 2021 | 1.79M 2.44M | Net Debt 2022 | 3.83M 5.22M | EV / Sales 2022 | - |
P/E ratio 2021 |
-16.6
x | P/E ratio 2022 |
-3.24
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 75.41% |
Managers | Title | Age | Since |
---|---|---|---|
Donal Schmidt
CEO | Chief Executive Officer | 63 | 19-11-14 |
D. Watler
DFI | Director of Finance/CFO | 75 | 19-11-14 |
Sean P. Berrier
PRN | Corporate Officer/Principal | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
D. Watler
DFI | Director of Finance/CFO | 75 | 19-11-14 |
Donal Schmidt
CEO | Chief Executive Officer | 63 | 19-11-14 |
1st Jan change | Capi. | |
---|---|---|
+42.38% | 6.26B | |
-15.86% | 4.49B | |
+6.36% | 3.29B | |
-11.28% | 3.12B | |
-3.23% | 2.5B | |
+45.24% | 1.94B | |
-7.89% | 1.68B | |
-0.98% | 1.63B | |
-11.32% | 1.56B |